Case number 2016-2169
Bayer Pharma AG v. Watson Laboratories, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | BAYER PHARMA AG v. WATSON LABORATORIES, INC. [OPINION] [precedential] (0) |
| Feb 20, 2018 | 76 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by Clerk of Court. [499296] [JAB] [Entered: 02/20/2018 11:58 AM] (1) |
| Feb 12, 2018 | 75 | ORDER filed denying [67] petition for panel rehearing filed by Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH; denying [67] petition for en banc rehearing filed by Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH. By: En Banc (Per Curiam). Service as of this date by Clerk of Court. [496985] [JAB] [Entered: 02/12/2018 10:45 AM] (2) |
| Jan 22, 2018 | 74 | 18 paper copies of the response [72] received from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. [491393] [JAB] [Entered: 01/22/2018 12:34 PM] (0) |
| Jan 22, 2018 | 73 | Notice to counsel for Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.: The record of this case indicates that the paper copies of the response to rehearing petition (see Fed. Cir. R. 35(c)(4)) have not been filed. The required paper copies should be received by the court on or before 01/24/2018. Service as of this date by Clerk of Court. [491298] [JAB] [Entered: 01/22/2018 10:53 AM] (0) |
| Jan 10, 2018 | 72 | RESPONSE of Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. to the petition for panel rehearing [67] filed by Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH in 16-2169 , petition for en banc rehearing [67] filed by Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH in 16-2169. Service: 01/10/2018 by email. [488716] [William Jay] [Entered: 01/10/2018 02:09 PM] (25) |
| Dec 13, 2017 | 71 | ORDER filed granting motion to extend time to file a response to the Combined Petition for Panel Rehearing and Rehearing En Banc [70] filed by Appellants Watson Laboratories, Inc. and Actavis Pharma, Inc. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [482458] [JAB] [Entered: 12/13/2017 03:22 PM] (2) |
| Dec 12, 2017 | 70 | MOTION of Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. to extend the time to file a response to the Combined Petition for Panel Rehearing and Rehearing En Banc until 01/10/2018. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/12/2017 by email. [482140] [William Jay] [Entered: 12/12/2017 03:51 PM] (9) |
| Dec 6, 2017 | 69 | The court invites a response from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. to the petition for panel rehearing filed by Appellees in 16-2169, petition for en banc rehearing filed by Appellees in 16-2169. [480605] [SJ] [Entered: 12/06/2017 01:25 PM] (1) |
| Dec 5, 2017 | 68 | 18 paper copies of the petition for panel rehearing [67], petition for en banc rehearing [67] received from Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. [480320] [SJ] [Entered: 12/05/2017 01:26 PM] (0) |
| Dec 1, 2017 | 67 | Petition for panel rehearing, for en banc rehearing filed by Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 12/01/2017 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 12/05/2017 [479759] [David Berl] [Entered: 12/01/2017 07:25 PM] (47) |
| Nov 1, 2017 | 66 | OPINION and JUDGMENT filed. The judgment or decision is: Reversed. (Precedential Opinion). (For the Court: Lourie,Circuit Judge; Moore,Circuit Judge and O'Malley,Circuit Judge). [472123] [SJ] [Entered: 11/01/2017 09:21 AM] (25) |
| Jun 9, 2017 | 65 | Submitted after ORAL ARGUMENT by William M. Jay for Watson Laboratories, Inc. and Actavis Pharma, Inc. and David I. Berl for Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH. Panel: Judge: Lourie , Judge: Moore , Judge: O'Malley. [437794] [SJ] [Entered: 06/09/2017 10:26 AM] (0) |
| May 11, 2017 | 64 | Response to oral argument order from the Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. designating William M. Jay as arguing attorney. Designated time for argument: 11 minutes. Designated time for rebuttal: 4 minutes. Service of other counsel by Notice of Docket Activity from this entry. [430800] [William Jay] [Entered: 05/11/2017 03:56 PM] (0) |
| May 9, 2017 | 63 | Response to oral argument order from the Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. designating David I. Berl as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [430133] [David Berl] [Entered: 05/09/2017 07:04 PM] (0) |
| Apr 21, 2017 | 62 | NOTICE OF CALENDARING. Panel: 1706O. Case scheduled Jun 09, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 203. Response to oral argument order due: 05/15/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 am and 9:30 am on the day of argument. Please review the Oral Argument Order. [426372] [JAB] [Entered: 04/21/2017 04:59 PM] (0) |
| Mar 16, 2017 | 61 | Notice from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. regarding conflicts with oral argument (May 2-5; June 6; July 10-14). Service: 03/16/2017 by email. [416294] [William Jay] [Entered: 03/16/2017 03:03 PM] (2) |
| Mar 6, 2017 | 60 | Notice from Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG regarding conflicts with oral argument (May 5, 2017, May 8, 2017, and same court session as Case Nos. 2016-2099, -2100, -2101, -2332, -2333, -2334 (Consolidated)). Service: 03/06/2017 by email. [412843] [David Berl] [Entered: 03/06/2017 05:00 PM] (1) |
| Mar 6, 2017 | 59 | Notice from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. regarding conflicts with oral argument (May 3-5; June 6; July 10-14). Service: 03/06/2017 by email. [412695] [William Jay] [Entered: 03/06/2017 12:05 PM] (2) |
| Feb 23, 2017 | 58 | 6 paper copies of the Confidential Joint Appendix (Vol. I-III) [50] received from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. [410553] [KW] [Entered: 02/24/2017 03:50 PM] (0) |
| Feb 21, 2017 | 57 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [MAY, JUN, JUL], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. [409291] [MJL] [Entered: 02/21/2017 03:54 PM] (0) |
| Feb 21, 2017 | 56 | 6 paper copies of the Reply Brief [47] received from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. [409118] [JCP] [Entered: 02/21/2017 12:29 PM] (0) |
| Feb 17, 2017 | 55 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 02/17/2017 by email. [408850] [David Berl] [Entered: 02/17/2017 05:58 PM] (3) |
| Feb 17, 2017 | 54 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 02/17/2017 by email. [408837] [William Jay] [Entered: 02/17/2017 04:59 PM] (3) |
| Feb 17, 2017 | 53 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Portions of the appendix ([50], [51]) were not text-searchable. CORRECTION: As a second reminder, all submissions to the court must be text-searchable in their entirety. For future filings, please ensure the document is text-searchable. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [408644] [MJL] [Entered: 02/17/2017 01:39 PM] (0) |
| Feb 17, 2017 | 52 | Notice to counsel: The record of this case indicates that the Certificate of Compliance with Fed. Cir. R. 11(d) has not been filed. IF any portion of the record in the trial court is subject to a protective order, counsel should promptly file the appropriate Certificate of Compliance using the Cert of Compliance Modification of Protective Order (R11/17) event which is found in the Forms and Certificates category. Service as of this date by Clerk of Court. [408642] [MJL] [Entered: 02/17/2017 01:36 PM] (0) |
| Feb 16, 2017 | 51 | APPENDIX FILED for Actavis Pharma, Inc. and Watson Laboratories, Inc. [49]. Number of Pages: 1321. Service: 02/16/2017 by email. Paper copies should be provided of the confidential version only. [408640] [MJL] [Entered: 02/17/2017 01:35 PM] (1321) |
| Feb 16, 2017 | 50 | CONFIDENTIAL JOINT APPENDIX FILED for Actavis Pharma, Inc. and Watson Laboratories, Inc. [48]. Number of Pages: 1342. Service: 02/16/2017 by email. The paper copies of the confidential version of the appendix should be received by the court on or before 02/27/2017. [408637] [MJL] [Entered: 02/17/2017 01:32 PM] (0) |
| Feb 16, 2017 | 49 | TENDERED from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Title: JOINT APPENDIX. Service: 02/16/2017 by email. [408459] [William Jay] [Entered: 02/16/2017 11:32 PM] (1321) |
| Feb 16, 2017 | 48 | TENDERED from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Title: CONFIDENTIAL JOINT APPENDIX Service: 02/16/2017 by email. [408458] [William Jay] [Entered: 02/16/2017 11:07 PM] (0) |
| Feb 9, 2017 | 47 | REPLY BRIEF FILED for Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. [46]. Number of Pages: 31. Service: 02/09/2017 by email. The paper copies of the brief should be received by the court on or before 02/21/2017. Appendix is due 02/16/2017. [406897] [MJL] [Entered: 02/13/2017 02:10 PM] (41) |
| Feb 9, 2017 | 46 | TENDERED from Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Title: REPLY BRIEF. Service: 02/09/2017 by email. [406223] [William Jay] [Entered: 02/09/2017 05:58 PM] (41) |
| Feb 3, 2017 | 45 | 6 paper copies of the Corrected Response Brief [44] received from Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. [404598] [KW] [Entered: 02/03/2017 02:16 PM] (0) |
| Jan 27, 2017 | 44 | CORRECTED BRIEF FILED for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG [43]. Number of Pages: 64. Service: 01/27/2017 by email. The paper copies of the brief should be received by the court on or before 02/06/2017. [402956] [MJL] [Entered: 01/30/2017 11:26 AM] (74) |
| Jan 27, 2017 | 43 | TENDERED from Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Title: CORRECTED RESPONSE BRIEF. Service: 01/27/2017 by email. [402843] [David Berl] [Entered: 01/27/2017 09:09 PM] (74) |
| Jan 26, 2017 | 42 | Amended Certificate of Interest for the Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 01/26/2017 by email. [402455] [William Jay] [Entered: 01/26/2017 05:01 PM] (2) |
| Jan 26, 2017 | 41 | NOTICE OF DEFICIENCY: The certificate of interest [40] filed by Appellants in 16-2169 is incomplete and therefore cannot be accepted for filing at this time. The answer to item #3 does not indicate which parent corporations/company applies for each party. You are being afforded the opportunity to correct the deficiency. The court encourages the parties to use the most recent certificate of interest form to better reflect this required deliniation. Please re-file a compliant certificate of interest promptly. [402427] [MJL] [Entered: 01/26/2017 04:15 PM] (0) |
| Jan 26, 2017 | 40 | Amended Certificate of Interest for the Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 01/26/2017 by email. [402402] [William Jay] [Entered: 01/26/2017 03:41 PM] (0) |
| Jan 25, 2017 | 39 | **TEXT ONLY** ORDER granting motion to extend time to file the reply brief [38] filed by Appellants Watson Laboratories, Inc. and Actavis Pharma, Inc.. The reply brief is due 02/09/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [401768] [MJL] [Entered: 01/25/2017 11:24 AM] (0) |
| Jan 24, 2017 | 38 | MOTION of Appellants Actavis Pharma, Inc. and Watson Laboratories, Inc. to extend the time to 02/09/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/24/2017 by email. [401560] [William Jay] [Entered: 01/24/2017 04:50 PM] (6) |
| Jan 24, 2017 | 37 | ORDER filed. The motion [34] is granted. The revised official caption is reflected in the order. Service: 01/24/2017 by clerk. [401274] [LMS] [Entered: 01/24/2017 11:14 AM] (2) |
| Jan 23, 2017 | 36 | NOTICE OF REJECTION: The Brief of Appellees Bayer Pharma AG, Bayer Intellectual Property GmBH, and Bayer Healthcare Pharmaceuticals Inc. [35] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected brief due 02/06/2017. Reply brief of Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc. is due 02/02/2017. Service as of this date by Clerk of Court. [400900] [MJL] [Entered: 01/23/2017 03:29 PM] (2) |
| Jan 19, 2017 | 35 | TENDERED from Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Title: RESPONSE BRIEF. Service: 01/19/2017 by email. [400549]. This brief has been rejected. See Doc. No. [36]. [David Berl] [Entered: 01/19/2017 07:55 PM] (0) |
| Jan 18, 2017 | 34 | MOTION of Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc. to modify the official caption. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/18/2017 by email. [399956] [William Jay] [Entered: 01/18/2017 01:20 PM] (3) |
| Oct 14, 2016 | 33 | ORDER granting motion to extend time to file the appellees' principal brief [32] filed by Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Pharma AG and Bayer Intellectual Property GmbH. No further extensions should be anticipated. The brief is due 01/19/2017. Service as of this date by Clerk of Court. [374493] [MJL] [Entered: 10/14/2016 04:20 PM] (2) |
| Oct 13, 2016 | 32 | MOTION of Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG to extend the time to 01/19/2017 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Response/Opposition is due 10/27/2016 [Consent: unopposed]. Service: 10/13/2016 by email. [374047] [David Berl] [Entered: 10/13/2016 09:50 PM] (7) |
| Oct 3, 2016 | 31 | 6 paper copies of the Opening Brief [28] received from Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc. [370975] [KW] [Entered: 10/03/2016 02:45 PM] (0) |
| Sep 30, 2016 | 30 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [370387] [MJL] [Entered: 09/30/2016 08:53 AM] (0) |
| Sep 30, 2016 | 29 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The addendum to Appellants' opening brief [27] was not text-searchable. CORRECTION: Please ensure future filings are entirely text-searchable. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [370386] [MJL] [Entered: 09/30/2016 08:52 AM] (0) |
| Sep 29, 2016 | 28 | BRIEF FILED for Appellants Actavis Pharma, Inc., Actavis, Inc., and Watson Laboratories, Inc. [27]. Number of Pages: 62. Service: 09/29/2016 by email. The paper copies of the brief should be received by the court on or before 10/05/2016. Brief of Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH, and Bayer Pharma AG is due 11/08/2016. [370385] [MJL] [Entered: 09/30/2016 08:51 AM] (108) |
| Sep 29, 2016 | 27 | TENDERED from Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Title: OPENING BRIEF. Service: 09/29/2016 by email. [370358] [William Jay] [Entered: 09/29/2016 07:00 PM] (108) |
| Aug 9, 2016 | 26 | **TEXT ONLY** ORDER granting motion to extend time to file the appellant's opening brief [25] filed by Appellants Actavis, Inc., Watson Laboratories, Inc. and Actavis Pharma, Inc.. The brief is due 09/29/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [357344] [MJL] [Entered: 08/09/2016 02:05 PM] (0) |
| Aug 8, 2016 | 25 | MOTION of Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc. to extend the time to 09/29/2016 at 11:59 pm to file the appellant/petitioner's principal brief. Response/Opposition is due 08/22/2016 [Consent: unopposed]. Service: 08/08/2016 by email. [356970] [William Jay] [Entered: 08/08/2016 03:24 PM] (8) |
| Jul 1, 2016 | 24 | Entry of appearance for Galina I. Fomenkova as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 07/01/2016 by email. [348193] [Galina Fomenkova] [Entered: 07/01/2016 05:06 PM] (2) |
| Jun 29, 2016 | 23 | Corrected Docketing Statement for the Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/29/2016 by email. [347527] [Elizabeth Holland] [Entered: 06/29/2016 04:34 PM] (4) |
| Jun 29, 2016 | 22 | Corrected Certificate of Interest for the Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/29/2016 by email. [347415] [David Berl] [Entered: 06/29/2016 01:21 PM] (2) |
| Jun 29, 2016 | 21 | NOTICE OF DEFICIENCY: The certificate of interest [7] filed by Appellees and the docketing statement [16] filed by Appellants in 16-2169 are incomplete and therefore cannot be accepted for filing at this time. Item #2 of the certificate of interest was left blank for all parties, and the question on related cases of the docketing statement was not answered. You are being afforded the opportunity to correct the deficiencies. Please ensure both documents are completely filled out. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [347380] [MJL] [Entered: 06/29/2016 12:15 PM] (0) |
| Jun 28, 2016 | 20 | Entry of appearance for David J. Zimmer as of counsel for Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347175] [David Zimmer] [Entered: 06/28/2016 05:41 PM] (2) |
| Jun 28, 2016 | 19 | Entry of appearance for Brian J. Robinson as of counsel for Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347173] [Brian Robinson] [Entered: 06/28/2016 05:26 PM] (2) |
| Jun 28, 2016 | 18 | Entry of appearance for William M. Jay as of counsel for Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347171] [William Jay] [Entered: 06/28/2016 05:23 PM] (2) |
| Jun 28, 2016 | 17 | Entry of appearance for Robert V. Cerwinski as of counsel for Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347169] [Robert Cerwinski] [Entered: 06/28/2016 05:19 PM] (2) |
| Jun 28, 2016 | 16 | Docketing Statement for the Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347165] [Elizabeth Holland] [Entered: 06/28/2016 05:15 PM] (0) |
| Jun 28, 2016 | 15 | Certificate of Interest for the Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347163] [Elizabeth Holland] [Entered: 06/28/2016 05:12 PM] (2) |
| Jun 28, 2016 | 14 | Entry of appearance for Elizabeth J. Holland as principal counsel for Appellants Actavis Pharma, Inc., Actavis, Inc. and Watson Laboratories, Inc.. Service: 06/28/2016 by email. [347160] [Elizabeth Holland] [Entered: 06/28/2016 05:08 PM] (2) |
| Jun 28, 2016 | 13 | Entry of appearance for Thomas S. Fletcher as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347120] [Thomas Fletcher] [Entered: 06/28/2016 03:39 PM] (2) |
| Jun 28, 2016 | 12 | Entry of appearance for Adam L. Perlman as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347085] [Adam Perlman] [Entered: 06/28/2016 02:59 PM] (2) |
| Jun 28, 2016 | 11 | Entry of appearance for Aaron P. Maurer as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347082] [Aaron Maurer] [Entered: 06/28/2016 02:56 PM] (2) |
| Jun 28, 2016 | 10 | Entry of appearance for Dov P. Grossman as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347079] [Dov Grossman] [Entered: 06/28/2016 02:54 PM] (2) |
| Jun 28, 2016 | 9 | Entry of appearance for Bruce R. Genderson as of counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347072] [Bruce Genderson] [Entered: 06/28/2016 02:50 PM] (2) |
| Jun 28, 2016 | 8 | Docketing Statement for the Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347070] [David Berl] [Entered: 06/28/2016 02:46 PM] (4) |
| Jun 28, 2016 | 7 | Certificate of Interest for the Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347066] [David Berl] [Entered: 06/28/2016 02:41 PM] (0) |
| Jun 28, 2016 | 6 | Entry of appearance for David I. Berl as principal counsel for Appellees Bayer Healthcare Pharmaceuticals, Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG. Service: 06/28/2016 by email. [347055] [David Berl] [Entered: 06/28/2016 02:33 PM] (2) |
| Jun 14, 2016 | 5 | Amended Certified list from the United States District Court for the District of Delaware. Service: 06/14/2016 by clerk.. [343397] [LN] [Entered: 06/14/2016 02:03 PM] (24) |
| Jun 14, 2016 | 4 | ORDER reactivating appeal. Entry of Appearance, Certificate of Interest, and Docketing Statement are due 6/28/2016. Appellant/Petitioner's brief is due 8/15/2016. Service as of this date by Clerk of Court. [343341] --[Edited 06/14/2016 by clerk - Reason: to correct docket text] [LN] [Entered: 06/14/2016 12:18 PM] (2) |
| Jun 14, 2016 | 3 | Copy of Order from United States District Court for the District of Delaware Amended Final Judgment. [343338] [LN] [Entered: 06/14/2016 12:14 PM] (2) |
| Jun 2, 2016 | 2 | ORDER deactivating appeal. Service as of this date by Clerk of Court. [340457] [LN] [Entered: 06/02/2016 05:14 PM] (2) |
| Jun 2, 2016 | 1 | Appeal docketed. Received: 06/02/2016. [340303]Entry of Appearance due 06/16/2016. Certificate of Interest is due on 06/16/2016. Docketing Statement due 06/16/2016. Appellant/Petitioner's brief is due 08/01/2016. [MJL] [Entered: 06/02/2016 01:19 PM] (68) |
